REGENERON PHARMACEUTICALS (REGN:NASDAQ)
$747.36 -2.05 (-0.2735%)
Analysed REGENERON PHARMACEUTICALS (REGN:NASDAQ) News Sources
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
21-04-2026
yahoo.com
Regeneron Announces Investor Conference Presentations
20-04-2026
yahoo.com
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
20-04-2026
yahoo.com
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
20-04-2026
yahoo.com
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
20-04-2026
yahoo.com
1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky
20-04-2026
yahoo.com
Regeneron Broadens Dupixent Use And Enters Radiopharmaceuticals With Telix
20-04-2026
yahoo.com
Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited
20-04-2026
yahoo.com
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
16-04-2026
yahoo.com
Trump's new tax cuts are helping millions: Treasury Sec. Bessent
15-04-2026
yahoo.com
What is the current price of REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The current price of REGENERON PHARMACEUTICALS (REGN:NASDAQ) is $747.36.
REGENERON PHARMACEUTICALS (REGN:NASDAQ) absolute price change since previous trading day?
The absolute price change of REGENERON PHARMACEUTICALS (REGN:NASDAQ) since the previous trading day is $-2.05.
REGENERON PHARMACEUTICALS (REGN:NASDAQ) percentage price change since previous trading day?
The percentage price change of REGENERON PHARMACEUTICALS (REGN:NASDAQ) since the previous trading day is -0.2735%.
What is the most recent average sentiment score for REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The most recent average sentiment score for REGENERON PHARMACEUTICALS (REGN:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for REGENERON PHARMACEUTICALS (REGN:NASDAQ)?
The most recent sentiment for REGENERON PHARMACEUTICALS (REGN:NASDAQ) is .
SEC-8K** Filing Available For REGENERON PHARMACEUTICALS (REGN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.